The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

AML MORE >>

In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the possibility of combination therapy in patients with AML. He highlights some of the most recent data to come out for this patient population, including for those harboring a TP53 or FLT3 mutation.

Latest JournalAll Journals >>

The Journal of Targeted Therapies in Cancer February 2019
The Journal of Targeted Therapies in Cancer
MORE >>
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.